A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Orano Med LLC
Turku University Hospital
Pfizer
OncoTherapy Science, Inc.
General Oncology, Inc.
DualityBio Inc.
OncoNano Medicine, Inc.
UNC Lineberger Comprehensive Cancer Center
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Gangnam Severance Hospital